Overview

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-24
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Phase:
PHASE3
Details
Lead Sponsor:
GlaxoSmithKline